Goldman Sachs Future Health Care Equity ETF
GDOC
New York Stock Exchange Arca- -
USD
- -
- -
- -
- -
(- -)
Recent
price
- -
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Goldman Sachs Future Health Care Equity ETF (GDOC) is an actively managed exchange-traded fund that seeks long-term growth of capital by investing at least 80% of its net assets in equity securities of U.S. and non-U.S. health care companies aligned with key innovation themes, including genomics, precision medicine, technology-enabled procedures, and digital health care; the fund typically holds 40 to 60 stocks across all market capitalizations with a focus on companies addressing unmet needs in areas such as chronic diseases, minimally invasive surgery, rare diseases, targeted oncology, genomics supply chain, connected devices, robotic surgery, gene/cell therapy, diagnostic testing, and digital transformation. Top holdings as of recent data include Eli Lilly and Co., Boston Scientific Corp., Abbott Laboratories, AbbVie Inc., and Insulet Corp., representing approximately 34.72% of the portfolio; the fund benchmarks against the MSCI ACWI Health Care Index and maintains sector allocations heavily weighted toward health care equipment and supplies (30.3%), biotechnology (27.7%), and pharmaceuticals (25.8%), with geographic exposure primarily in North America (75.2%), Europe (17.4%), Japan (2.6%), and other regions. Launched on November 9, 2021, and listed on NYSE Arca, GDOC is issued by Goldman Sachs ETF Trust and managed by Goldman Sachs Asset Management, L.P., a division of The Goldman Sachs Group, Inc., founded in 1869 and headquartered at 200 West Street, New York, New York. In recent developments, the fund reported net assets of approximately $20-26 million as of mid-2025 with a total expense ratio of 0.75%; it achieved a 52-week high in November 2025 amid strong health care sector momentum driven by factors like aging populations, AI integration, precision medicine advances, and elevated M&A activity, while quarterly updates through 2Q 2024 highlighted portfolio adjustments such as adding AbbVie for its immunology and neuroscience growth post-Humira patent cliff and exiting Bristol-Myers Squibb due to underperformance. The fund has continued to emphasize innovation tailwinds from blockbuster categories like obesity (GLP-1 drugs), Alzheimer's treatments, medtech including robotic surgery and structural heart interventions, and bioprocessing amid new drug launches, with constructive outlooks for 2H 2024 and 2025 despite policy uncertainties around Medicare pricing.